Data from Pharmawand - Curated by EPG Health - Date added 13 February 2018

Pacira Pharmaceuticals, Inc. announced that the FDA has posted briefing materials for the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) meeting that will review the company’s supplemental New Drug Application seeking expansion of the current Exparel (bupivacaine liposome injectable suspension) label for infiltration to include use as a nerve block for regional analgesia.

The Advisory Committee meeting is scheduled for February 14-15, 2018. The sNDA filing is based on positive data from a Phase III study of Exparel in femoral nerve block for total knee arthroplasty (lower extremity) and a Phase III study of Exparel in brachial plexus block for shoulder surgeries (upper extremity). It includes data from eight company-sponsored studies with safety and pharmacokinetic data through 120 hours. In addition, the sNDA includes data from two investigator-initiated studies that provide additional experience in smaller, peripheral nerve block settings.

The Prescription Drug User Fee Act (PDUFA) date for completion of the FDA’s review of the company’s sNDA for ExparelL is April 6, 2018.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

ESICM LIVES Highlights

ESICM LIVES Highlights

ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.

Pain, Agitation and Delirium (PAD) Management

Pain, Agitation and Delirium (PAD) Management

Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.

+ 4 more

Load more

Related Content